Petrylak, D. P., Ratta, R., Matsubara, N., Korbenfeld, E. P., Gafanov, R., Mourey, L., … Fizazi, K. (2023). Patient-reported outcomes (PROs) in KEYNOTE-921: Pembrolizumab (pembro) plus docetaxel for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). In JOURNAL OF CLINICAL ONCOLOGY (Vol. 41).

Petrylak, Daniel P., Raffaele Ratta, Nobuaki Matsubara, Ernesto Pablo Korbenfeld, Rustem Gafanov, Loic Mourey, Tilman Todenho Spacing Diaeresis Fer, et al. “Patient-reported outcomes (PROs) in KEYNOTE-921: Pembrolizumab (pembro) plus docetaxel for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 41, 2023.

Petrylak DP, Ratta R, Matsubara N, Korbenfeld EP, Gafanov R, Mourey L, et al. Patient-reported outcomes (PROs) in KEYNOTE-921: Pembrolizumab (pembro) plus docetaxel for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). In: JOURNAL OF CLINICAL ONCOLOGY. 2023.

Petrylak, Daniel P., et al. “Patient-reported outcomes (PROs) in KEYNOTE-921: Pembrolizumab (pembro) plus docetaxel for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).” JOURNAL OF CLINICAL ONCOLOGY, vol. 41, 2023.

Petrylak DP, Ratta R, Matsubara N, Korbenfeld EP, Gafanov R, Mourey L, Fer TTSD, Gurney H, Kramer G, Bergman AM, Zalewski P, De Santis M, Armstrong AJ, Gerritsen WR, Pachynski RK, Saretsky TL, Ghate SR, Li XT, Schloss C, Fizazi K. Patient-reported outcomes (PROs) in KEYNOTE-921: Pembrolizumab (pembro) plus docetaxel for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). JOURNAL OF CLINICAL ONCOLOGY. 2023.